Hercules, CA — November 28, 2012 — Bio-Rad Laboratories, Inc. today announced the launch of its new CFX96 Touch Deep Well real-time PCR detection system, an ideal solution for researchers conducting real-time PCR (qPCR) experiments in large-volume reactions.
Designed and validated for detecting up to five targets in reaction volumes between 10 and 125 µl, the CFX96 Touch Deep Well system offers precise quantification and excellent uniformity with high thermal performance. The redesigned honeycomb thermal block contains six independently controlled thermal electric units, allowing researchers to perform uniform, accurate experiments in large reaction volumes without compromising their quantitative data.
Additional benefits of the CFX96 Touch Deep Well system include:
· Stand-alone operation — view real-time data traces on an intuitive LCD touch screen
· Effortless optimization — optimize assays quickly with built-in thermal gradient
Meaningful data analysis — analyze experiments easily with advanced data grouping tools such as clustergram and heat map in CFX Manager™ software
For further details about the CFX96 Touch Deep Well real-time PCR detection system, please visit www.bio-rad.com/cfx96deepwell
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
312-997-2436 x 112